Paliperidone ER

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Affective Psychosis, Bipolar

Conditions

Affective Psychosis, Bipolar, Bipolar Disorder, Mania

Trial Timeline

Apr 1, 2006 → Aug 1, 2007

NCT ID

NCT00309686

About Paliperidone ER

Paliperidone ER is a phase 3 stage product being developed by Johnson & Johnson for Affective Psychosis, Bipolar. The current trial status is completed. This product is registered under clinical trial identifier NCT00309686. Target conditions include Affective Psychosis, Bipolar, Bipolar Disorder, Mania.

What happened to similar drugs?

2 of 7 similar drugs in Affective Psychosis, Bipolar were approved

Approved (2) Terminated (0) Active (5)

✅Haloperidol + OlanzapineEli LillyApproved

🔄Placebo + Paliperidone ER + Paliperidone ERJohnson & JohnsonPhase 3

🔄Paliperidone ER + Paliperidone ER + PlaceboJohnson & JohnsonPhase 3

🔄Quetiapine fumarate (Seroquel) SRAstraZenecaPhase 3

🔄Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + ZiprasidonePfizerPhase 3

✅ZiprasidonePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02075528	Approved	Completed	Jul 1, 2009	Jul 1, 2012	Schizophrenia
NCT01577186	Approved	Completed	Jul 1, 2008	Jun 1, 2009	Schizophrenia
NCT01577160	Approved	Completed	May 1, 2008	Apr 1, 2009	Schizophrenia
NCT00757705	Approved	Completed	Mar 1, 2008	May 1, 2009	Schizophrenia
NCT00791193	Phase 1	Completed	Mar 1, 2007	May 1, 2007	Schizophrenia
NCT00790777	Phase 1	Completed	Mar 1, 2007	May 1, 2007	Schizophrenia
NCT00791167	Phase 1	Completed	Jun 1, 2006	Aug 1, 2006	Schizophrenia
NCT00309686	Phase 3	Completed	Apr 1, 2006	Aug 1, 2007	Affective Psychosis, Bipolar
NCT00791713	Phase 1	Completed	Mar 1, 2006	Jul 1, 2006	Schizophrenia
NCT00791622	Phase 1	Completed	Jan 1, 2006	Jun 1, 2006	Schizophrenia
NCT00105326	Phase 2	Completed	Feb 1, 2005	Aug 1, 2005	Schizophrenia
NCT00085748	Phase 3	Completed	Aug 1, 2004	May 1, 2005	Schizophrenia
NCT00083668	Phase 3	Completed	Apr 1, 2004	May 1, 2005	Schizophrenia
NCT00078039	Phase 3	Completed	Mar 1, 2004	Jan 1, 2005	Schizophrenia
NCT00086320	Phase 3	Completed	Mar 1, 2004	Aug 1, 2005	Schizophrenia
NCT00077714	Phase 3	Completed	Jan 1, 2004	Jan 1, 2005	Schizophrenia
NCT00796185	Phase 1	Completed	Aug 1, 2003	Jan 1, 2004	Schizophrenia
NCT00796471	Phase 1	Completed	Jun 1, 2003	Aug 1, 2003	Schizophrenia

Competing Products

14 competing products in Affective Psychosis, Bipolar

See all competitors

Product	Company	Stage	Hype Score
Haloperidol + Olanzapine	Eli Lilly	Approved	43
Lurasidone HCl	Sumitomo Pharma	Phase 1	29
Placebo + Paliperidone ER + Paliperidone ER	Johnson & Johnson	Phase 3	40
Paliperidone ER + Paliperidone ER + Placebo	Johnson & Johnson	Phase 3	40
Quetiapine fumarate (Seroquel) SR	AstraZeneca	Phase 3	40
Quetiapine fumarate (Seroquel) SR	AstraZeneca	Phase 3	40
RO6889450 + Placebo + Risperidone	Roche	Phase 2	35
RO6889450 + Placebo	Roche	Phase 2	27
AMG 581 + Placebo + Midazolam	Amgen	Phase 1	29
AMG 581 + Placebo	Amgen	Phase 1	29
Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone + Aripiprazole + Olanzapine + Risperidone + Quetiapine + Ziprasidone	Pfizer	Phase 3	40
Ziprasidone	Pfizer	Approved	43
ziprasidone	Pfizer	Pre-clinical	26
Ziprasidone + Sertraline + Haloperidol	Pfizer	Phase 2/3	38